首页> 美国卫生研究院文献>BioMed Research International >Novel Stromal Biomarkers in Human Breast Cancer Tissues Provide Evidence for the More Malignant Phenotype of Estrogen Receptor-Negative Tumors
【2h】

Novel Stromal Biomarkers in Human Breast Cancer Tissues Provide Evidence for the More Malignant Phenotype of Estrogen Receptor-Negative Tumors

机译:人类乳腺癌组织中的新型基质生物标志物为雌激素受体阴性肿瘤的更恶性表型提供了证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Research efforts were focused on genetic alterations in epithelial cancer cells. Epithelial-stromal interactions play a crucial role in cancer initiation, progression, invasion, angiogenesis, and metastasis; however, the active role of stroma in human breast tumorigenesis in relation to estrogen receptor (ER) status of epithelial cells has not been explored. Using proteomics and biochemical approaches, we identified two stromal proteins in ER-positive and ER-negative human breast cancer tissues that may affect malignant transformation in breast cancer. Two putative biomarkers, T-cell receptor alpha (TCR-α) and zinc finger and BRCA1-interacting protein with a KRAB domain (ZBRK1), were detected in leukocytes of ER-positive and endothelial cells of ER-negative tissues, respectively. Our data suggest an immunosuppressive role of leukocytes in invasive breast tumors, propose a multifunctional nature of ZBRK1 in estrogen receptor regulation and angiogenesis, and demonstrate the aggressiveness of ER-negative human breast carcinomas. This research project may identify new stromal drug targets for the treatment of breast cancer patients.
机译:研究工作集中在上皮癌细胞的遗传改变上。上皮-基质相互作用在癌症的发生,发展,侵袭,血管生成和转移中起着至关重要的作用。然而,尚未探讨基质在人乳腺肿瘤发生中与上皮细胞雌激素受体(ER)状态有关的积极作用。使用蛋白质组学和生物化学方法,我们在ER阳性和ER阴性的人类乳腺癌组织中鉴定了两种基质蛋白,这些蛋白可能会影响乳腺癌的恶性转化。在ER阳性组织的白细胞和ER阴性组织的内皮细胞中分别检测到两个推定的生物标志物,即T细胞受体α(TCR-α)和具有KRAB结构域的锌指和BRCA1相互作用蛋白(ZBRK1)。我们的数据表明白细胞在侵袭性乳腺肿瘤中具有免疫抑制作用,提出ZBRK1在雌激素受体调节和血管生成中具有多功能性质,并证明ER阴性人类乳腺癌的侵袭性。该研究项目可能会确定治疗乳腺癌患者的新基质药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号